Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Steurer M, Montillo M, Scarfò L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Frömming A, Dümmler T, Riecke K, Baumann M, Beyer D, Vauléon S, Ghia P, Foà R, Caligaris-Cappio F, Gobbi M.

Haematologica. 2019 May 16. pii: haematol.2018.205930. doi: 10.3324/haematol.2018.205930. [Epub ahead of print]

2.

IL1R8 Deficiency Drives Autoimmunity-Associated Lymphoma Development.

Riva F, Ponzoni M, Supino D, Bertilaccio MTS, Polentarutti N, Massara M, Pasqualini F, Carriero R, Innocenzi A, Anselmo A, Veliz-Rodriguez T, Simonetti G, Anders HJ, Caligaris-Cappio F, Mantovani A, Muzio M, Garlanda C.

Cancer Immunol Res. 2019 Jun;7(6):874-885. doi: 10.1158/2326-6066.CIR-18-0698. Epub 2019 Apr 24.

PMID:
31018956
3.

A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression.

Farinello D, Wozińska M, Lenti E, Genovese L, Bianchessi S, Migliori E, Sacchetti N, di Lillo A, Bertilaccio MTS, de Lalla C, Valsecchi R, Gleave SB, Lligé D, Scielzo C, Mauri L, Ciampa MG, Scarfò L, Bernardi R, Lazarevic D, Gonzalez-Farre B, Bongiovanni L, Campo E, Cerutti A, Ponzoni M, Pattini L, Caligaris-Cappio F, Ghia P, Brendolan A.

Nat Commun. 2018 May 3;9(1):1787. doi: 10.1038/s41467-018-04150-7.

4.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ.

Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.

5.

Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.

Belloni D, Heltai S, Ponzoni M, Villa A, Vergani B, Pecciarini L, Marcatti M, Girlanda S, Tonon G, Ciceri F, Caligaris-Cappio F, Ferrarini M, Ferrero E.

Haematologica. 2018 Apr;103(4):707-716. doi: 10.3324/haematol.2017.167486. Epub 2018 Jan 11.

6.

Pathogen-specific B-cell receptors drive chronic lymphocytic leukemia by light-chain-dependent cross-reaction with autoantigens.

Jiménez de Oya N, De Giovanni M, Fioravanti J, Übelhart R, Di Lucia P, Fiocchi A, Iacovelli S, Efremov DG, Caligaris-Cappio F, Jumaa H, Ghia P, Guidotti LG, Iannacone M.

EMBO Mol Med. 2017 Nov;9(11):1482-1490. doi: 10.15252/emmm.201707732.

7.

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC.

Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.

8.

Immunotherapy in lymphoma.

Ansell SM, Caligaris-Cappio F, Maloney DG.

Hematol Oncol. 2017 Jun;35 Suppl 1:88-91. doi: 10.1002/hon.2408. Review. No abstract available.

PMID:
28591421
9.

Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.

Gorini F, Azzimonti L, Delfanti G, Scarfò L, Scielzo C, Bertilaccio MT, Ranghetti P, Gulino A, Doglioni C, Di Napoli A, Capri M, Franceschi C, Caligaris-Cappio F, Ghia P, Bellone M, Dellabona P, Casorati G, de Lalla C.

Blood. 2017 Jun 29;129(26):3440-3451. doi: 10.1182/blood-2016-11-751065. Epub 2017 May 2.

10.

B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia.

Galletti G, Caligaris-Cappio F, Bertilaccio MT.

Leukemia. 2016 Dec;30(12):2293-2301. doi: 10.1038/leu.2016.261. Epub 2016 Sep 28. Review.

PMID:
27677742
11.

Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA.

J Immunol. 2016 Sep 15;197(6):2522-31. doi: 10.4049/jimmunol.1600915. Epub 2016 Aug 17.

12.

Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models.

Bianco M, Gasparri A, Generoso L, Assi E, Colombo B, Scarfò L, Bertilaccio MT, Scielzo C, Ranghetti P, Dondossola E, Ponzoni M, Caligaris-Cappio F, Ghia P, Corti A.

Oncotarget. 2016 Jul 5;7(27):41725-41736. doi: 10.18632/oncotarget.9407.

13.

Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression.

Galletti G, Scielzo C, Barbaglio F, Rodriguez TV, Riba M, Lazarevic D, Cittaro D, Simonetti G, Ranghetti P, Scarfò L, Ponzoni M, Rocchi M, Corti A, Anselmo A, van Rooijen N, Klein C, Ries CH, Ghia P, De Palma M, Caligaris-Cappio F, Bertilaccio MTS.

Cell Rep. 2016 Feb 23;14(7):1748-1760. doi: 10.1016/j.celrep.2016.01.042. Epub 2016 Feb 11.

14.

Chromogranin A Is Preferentially Cleaved into Proangiogenic Peptides in the Bone Marrow of Multiple Myeloma Patients.

Bianco M, Gasparri AM, Colombo B, Curnis F, Girlanda S, Ponzoni M, Bertilaccio MT, Calcinotto A, Sacchi A, Ferrero E, Ferrarini M, Chesi M, Bergsagel PL, Bellone M, Tonon G, Ciceri F, Marcatti M, Caligaris-Cappio F, Corti A.

Cancer Res. 2016 Apr 1;76(7):1781-91. doi: 10.1158/0008-5472.CAN-15-1637. Epub 2016 Feb 11.

15.

HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.

Valsecchi R, Coltella N, Belloni D, Ponente M, Ten Hacken E, Scielzo C, Scarfò L, Bertilaccio MT, Brambilla P, Lenti E, Martinelli Boneschi F, Brendolan A, Ferrero E, Ferrarini M, Ghia P, Tonon G, Ponzoni M, Caligaris-Cappio F, Bernardi R.

Blood. 2016 Apr 21;127(16):1987-97. doi: 10.1182/blood-2015-07-657056. Epub 2016 Jan 29.

16.

Directing CLL-cell traffic.

Caligaris-Cappio F.

Blood. 2015 Sep 10;126(11):1267-8. doi: 10.1182/blood-2015-07-657890. No abstract available.

17.

Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Fonte E, Agathangelidis A, Reverberi D, Ntoufa S, Scarfò L, Ranghetti P, Cutrona G, Tedeschi A, Xochelli A, Caligaris-Cappio F, Ponzoni M, Belessi C, Davis Z, Piris MA, Oscier D, Ghia P, Stamatopoulos K, Muzio M.

Haematologica. 2015 Nov;100(11):1460-8. doi: 10.3324/haematol.2014.119933. Epub 2015 Aug 20.

18.

High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, Tarella C, Di Nicola M, D'Arco AM, Doa G, Bruno-Ventre M, Assanelli A, Foppoli M, Citterio G, Fanni A, Mulè A, Caligaris-Cappio F, Ciceri F.

J Clin Oncol. 2015 Nov 20;33(33):3903-10. doi: 10.1200/JCO.2015.61.1236. Epub 2015 Aug 17.

PMID:
26282634
19.

Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, Scielzo C.

PLoS One. 2015 Jul 29;10(7):e0134748. doi: 10.1371/journal.pone.0134748. eCollection 2015. No abstract available.

20.

Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line.

Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MT, Ranghetti P, Ponzoni M, Leone G, De Pascali V, Pecciarini L, Ghia P, Caligaris-Cappio F, Scielzo C.

PLoS One. 2015 Jun 25;10(6):e0130195. doi: 10.1371/journal.pone.0130195. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0134748.

21.

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.

Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR.

Leuk Res. 2015 May;39(5):495-500. doi: 10.1016/j.leukres.2015.02.001. Epub 2015 Feb 7.

22.

Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis.

Belloni D, Marcatti M, Ponzoni M, Ciceri F, Veschini L, Corti A, Caligaris Cappio F, Ferrarini M, Ferrero E.

Exp Cell Res. 2015 Jan 1;330(1):1-12. doi: 10.1016/j.yexcr.2014.10.017. Epub 2014 Oct 24.

PMID:
25447443
23.

From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia.

Apollonio B, Bertilaccio MT, Restuccia U, Ranghetti P, Barbaglio F, Ghia P, Caligaris-Cappio F, Scielzo C.

J Vis Exp. 2014 Oct 19;(92):e51942. doi: 10.3791/51942.

24.

Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.

Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarfò L, Sassone M, Govi S, Caligaris-Cappio F.

Br J Haematol. 2015 Mar;168(5):654-62. doi: 10.1111/bjh.13194. Epub 2014 Oct 14.

PMID:
25312994
25.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.

26.

SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.

Simonetti G, Bertilaccio MT, Rodriguez TV, Apollonio B, Dagklis A, Rocchi M, Innocenzi A, Casola S, Winkler TH, Nitschke L, Ponzoni M, Caligaris-Cappio F, Ghia P.

Haematologica. 2014 Aug;99(8):1356-64. doi: 10.3324/haematol.2013.100230. Epub 2014 May 23.

27.

Anergy: the CLL cell limbo.

Caligaris-Cappio F.

Blood. 2014 May 22;123(21):3214-5. doi: 10.1182/blood-2014-04-565408. No abstract available.

28.

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G.

Nat Med. 2014 Jun;20(6):599-606. doi: 10.1038/nm.3562. Epub 2014 May 11.

29.

Chronic lymphocytic leukemia (CLL): a model for understanding and treating chronic B-cell malignancies.

Caligaris-Cappio F.

Rinsho Ketsueki. 2013 Oct;54(10):1838-42. Review. No abstract available.

PMID:
24064834
30.

Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy.

Ferrarini M, Steimberg N, Ponzoni M, Belloni D, Berenzi A, Girlanda S, Caligaris-Cappio F, Mazzoleni G, Ferrero E.

PLoS One. 2013 Aug 26;8(8):e71613. doi: 10.1371/journal.pone.0071613. eCollection 2013. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/d7d8e0a7-aa3d-4620-98e5-c5a7bbf31dc8.

31.

How the microenvironment wires the natural history of chronic lymphocytic leukemia.

Caligaris-Cappio F, Bertilaccio MT, Scielzo C.

Semin Cancer Biol. 2014 Feb;24:43-8. doi: 10.1016/j.semcancer.2013.06.010. Epub 2013 Jul 2. Review.

PMID:
23831274
32.

Targeting B-cell anergy in chronic lymphocytic leukemia.

Apollonio B, Scielzo C, Bertilaccio MT, Ten Hacken E, Scarfò L, Ranghetti P, Stevenson F, Packham G, Ghia P, Muzio M, Caligaris-Cappio F.

Blood. 2013 May 9;121(19):3879-88, S1-8. doi: 10.1182/blood-2012-12-474718. Epub 2013 Mar 4.

33.

Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.

ten Hacken E, Scielzo C, Bertilaccio MT, Scarfò L, Apollonio B, Barbaglio F, Stamatopoulos K, Ponzoni M, Ghia P, Caligaris-Cappio F.

Blood. 2013 Mar 21;121(12):2264-73. doi: 10.1182/blood-2012-09-457119. Epub 2013 Jan 16.

34.

Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene.

Casucci M, Perna SK, Falcone L, Camisa B, Magnani Z, Bernardi M, Crotta A, Tresoldi C, Fleischhauer K, Ponzoni M, Gregori S, Caligaris Cappio F, Ciceri F, Bordignon C, Cignetti A, Bondanza A, Bonini C.

Mol Ther. 2013 Feb;21(2):466-75. doi: 10.1038/mt.2012.227. Epub 2012 Nov 13.

35.

In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors.

Fonte E, Apollonio B, Scarfò L, Ranghetti P, Fazi C, Ghia P, Caligaris-Cappio F, Muzio M.

Clin Cancer Res. 2013 Jan 15;19(2):367-79. doi: 10.1158/1078-0432.CCR-12-1922. Epub 2012 Dec 5.

36.

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Ghielmini M, Vitolo U, Kimby E, Montoto S, Walewski J, Pfreundschuh M, Federico M, Hoskin P, McNamara C, Caligaris-Cappio F, Stilgenbauer S, Marcus R, Trneny M, Dreger P, Montserrat E, Dreyling M; Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma.

Ann Oncol. 2013 Mar;24(3):561-76. doi: 10.1093/annonc/mds517. Epub 2012 Nov 21.

37.

Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.

Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ.

Hematol Oncol. 2013 Sep;31(3):143-50. doi: 10.1002/hon.2037. Epub 2012 Nov 14.

PMID:
23161567
38.

Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.

Bertilaccio MT, Scielzo C, Simonetti G, Ten Hacken E, Apollonio B, Ghia P, Caligaris-Cappio F.

Leukemia. 2013 Mar;27(3):534-40. doi: 10.1038/leu.2012.268. Epub 2012 Sep 13. Review.

PMID:
23041721
39.

Toll-like Receptors in Chronic Lymphocytic Leukemia.

Muzio M, Fonte E, Caligaris-Cappio F.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012055. doi: 10.4084/MJHID.2012.055. Epub 2012 Aug 9.

40.

Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma.

Ferreri AJ, Bruno Ventre M, Donadoni G, Cattaneo C, Fumagalli L, Foppoli M, Mappa S, Govi S, Di Nicola M, Rossi G, Tirelli U, Caligaris-Cappio F, Spina M, Re A.

Br J Haematol. 2012 Oct;159(2):252-5. doi: 10.1111/bjh.12020. Epub 2012 Aug 25. No abstract available.

PMID:
22924636
41.

Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors.

Ntoufa S, Vardi A, Papakonstantinou N, Anagnostopoulos A, Aleporou-Marinou V, Belessi C, Ghia P, Caligaris-Cappio F, Muzio M, Stamatopoulos K.

Mol Med. 2012 Dec 6;18:1281-91. doi: 10.2119/molmed.2011.00480.

42.

Monoclonal B-cell lymphocytosis: right track or red herring?

Ghia P, Caligaris-Cappio F.

Blood. 2012 May 10;119(19):4358-62. doi: 10.1182/blood-2012-01-404681. Epub 2012 Mar 14. Review.

43.

General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL.

Fazi C, Scarfò L, Pecciarini L, Cottini F, Dagklis A, Janus A, Talarico A, Scielzo C, Sala C, Toniolo D, Caligaris-Cappio F, Ghia P.

Blood. 2011 Dec 15;118(25):6618-25. doi: 10.1182/blood-2011-05-357251. Epub 2011 Aug 29.

44.

Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment.

Ponzoni M, Doglioni C, Caligaris-Cappio F.

Semin Diagn Pathol. 2011 May;28(2):161-6. Review.

PMID:
21842701
45.

Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients.

Arvaniti E, Ntoufa S, Papakonstantinou N, Touloumenidou T, Laoutaris N, Anagnostopoulos A, Lamnissou K, Caligaris-Cappio F, Stamatopoulos K, Ghia P, Muzio M, Belessi C.

Haematologica. 2011 Nov;96(11):1644-52. doi: 10.3324/haematol.2011.044792. Epub 2011 Jul 12.

46.

The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia.

Scielzo C, Apollonio B, Scarfò L, Janus A, Muzio M, Ten Hacken E, Ghia P, Caligaris-Cappio F.

Leukemia. 2011 Nov;25(11):1760-7. doi: 10.1038/leu.2011.149. Epub 2011 Jun 28. Erratum in: Leukemia. 2011 Nov;25(11):1794.

PMID:
21709686
47.

A matter of debate in chronic lymphocytic leukemia: is the occurrence of autoimmune disorders an indicator of chronic lymphocytic leukemia therapy?

Strati P, Caligaris-Cappio F.

Curr Opin Oncol. 2011 Sep;23(5):455-60. doi: 10.1097/CCO.0b013e328348c683. Review.

PMID:
21681094
48.

Lack of TIR8/SIGIRR triggers progression of chronic lymphocytic leukemia in mouse models.

Bertilaccio MT, Simonetti G, Dagklis A, Rocchi M, Rodriguez TV, Apollonio B, Mantovani A, Ponzoni M, Ghia P, Garlanda C, Caligaris-Cappio F, Muzio M.

Blood. 2011 Jul 21;118(3):660-9. doi: 10.1182/blood-2011-01-329870. Epub 2011 Jun 7. Erratum in: Blood. 2012 Sep 27;120(13):2773.

49.

Inflammation, the microenvironment and chronic lymphocytic leukemia.

Caligaris-Cappio F.

Haematologica. 2011 Mar;96(3):353-5. doi: 10.3324/haematol.2010.039446. No abstract available.

50.

Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.

Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C.

Clin Cancer Res. 2011 Apr 1;17(7):1964-72. doi: 10.1158/1078-0432.CCR-10-1376. Epub 2011 Feb 9.

Supplemental Content

Loading ...
Support Center